Display options
Share it on

Exp Clin Cardiol. 2001;6(2):109-13.

Factors determining spontaneous ventricular defibrillation.

Experimental and clinical cardiology

N Tribulova, M Manoach

Affiliations

  1. Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic, and.

PMID: 20428273 PMCID: PMC2859015

Abstract

Ventricular fibrillation (VF) is defined as a sustained, fatal reentrant arrhythmia that never terminates spontaneously and requires artificial electrical defibrillation. For many years it was believed that spontaneous ventricular defibrillation (SVD) appears only in hearts with small muscle mass that cannot continue fibrillating. SVD appears even in humans, and some drugs transform sustained VF into a transient VF, reverting spontaneously into sinus rhythm. The present criteria for VF were based on the wavelength theory. Accordingly, the persistence of fibrillation depends on the wavelength of the reentrant impulse. Fibrillation can be sustained only if the reentrant circuit is smaller than the length of the refractory tissue. Following this assumption, lengthening of action potential duration (APD) and effective refractory period (ERP) were accepted as factors that determine antiarrhythmic defibrillating ability. The results of recent studies questioned this postulation and clearly showed that prolongation of APD is proarrhythmic. In examining the differences between transient and sustained VF in various mammals, it was hypothesized that SVD requires a high degree of myocardial gap junctional coupling and synchronization. Thus, any compound or condition that enhances intercellular coupling and synchronization or attenuates the dispersion of refractoriness can facilitate SVD. Because one of the main factors involved in intercellular uncoupling is an excess concentration of cytoplasmic free Ca(2+), it seems plausible that a compound that protects against Ca(2+) overload and has a positive inotropic effect can serve as a potent defibrillating agent. Evaluation of the anti-arrhythmic properties of various defibrillating compounds showed that a defibrillating drug has the ability to prevent or to attenuate Ca(2+) overload. By decreasing increased diastolic Ca(2+) concentration, they enhance intercellular coupling and synchronization, and consequently facilitate SVD, while prolongation of APD or ERP facilitates the appearance of arrhythmias and VF. The novel approach based on upregulation of intercellular coupling to enhance synchronization and on decreased dispersion of refractoriness without prolongation of APD should be taken into consideration in future development of new potent cardioprotective-defibrillating drugs.

Keywords: Antiarrhythmic/defibrillating compounds; Ca2+ overload; Intercellular coupling; Spontaneous ventricular defibrillation; Ventricular fibrillation

References

  1. Circ Res. 1981 Sep;49(3):815-20 - PubMed
  2. Circ Res. 1998 Feb 9;82(2):279-93 - PubMed
  3. Circulation. 1983 Feb;67(2):434-40 - PubMed
  4. Gen Physiol Biophys. 1999 Dec;18 Suppl 1:15-8 - PubMed
  5. Circ Res. 1981 Jan;48(1):39-54 - PubMed
  6. Am J Cardiol. 1968 Apr;21(4):530-43 - PubMed
  7. Am J Cardiol. 1968 Apr;21(4):504-12 - PubMed
  8. Circ Res. 1988 Feb;62(2):395-410 - PubMed
  9. Life Sci. 1993;53(1):1-19 - PubMed
  10. Br Heart J. 1972 Apr;34(4):396-402 - PubMed
  11. Br Heart J. 1965 Jan;27:62-8 - PubMed
  12. J Cardiovasc Pharmacol. 1982 May-Jun;4(3):430-5 - PubMed
  13. Circ Res. 1982 Sep;51(3):347-62 - PubMed
  14. J Basic Clin Physiol Pharmacol. 1994 Jan-Mar;5(1):1-17 - PubMed
  15. Circ Res. 1986 Mar;58(3):356-71 - PubMed
  16. Eur Heart J. 1985 Nov;6 Suppl D:63-70 - PubMed
  17. Heart Vessels Suppl. 1987;2:56-68 - PubMed
  18. Heart Vessels. 1996;11(6):281-8 - PubMed
  19. Circ Res. 1976 Aug;39(2):168-77 - PubMed
  20. Life Sci. 1992;51(17):PL159-64 - PubMed
  21. J Cardiovasc Pharmacol. 1990 Dec;16(6):871-80 - PubMed
  22. Eur J Pharmacol. 1988 Jul 14;151(3):389-97 - PubMed
  23. J Mol Cell Cardiol. 1995 Jan;27(1):37-44 - PubMed
  24. Isr J Med Sci. 1979 May;15(5):443-7 - PubMed
  25. Am J Cardiol. 1993 Aug 12;72(4):72A-79A - PubMed
  26. J Physiol. 1987 Jan;382:193-211 - PubMed
  27. J Clin Pharmacol New Drugs. 1972 Apr;12(4):127-35 - PubMed
  28. Circulation. 1992 May;85(5):1865-78 - PubMed
  29. J Physiol. 1913 Jul 18;46(4-5):349-83 - PubMed
  30. J Basic Clin Physiol Pharmacol. 1993 Oct-Dec;4(4):281-90 - PubMed
  31. J Cardiovasc Electrophysiol. 1995 Jul;6(7):584-9 - PubMed
  32. Int J Cardiol. 1988 Dec;21(3):211-7 - PubMed
  33. Am Heart J. 1949 Jan;37(1):21-35 - PubMed
  34. Heart Vessels. 1995;10(4):185-9 - PubMed
  35. Circulation. 1999 Apr 27;99(16):2220-1 - PubMed
  36. Prog Cardiovasc Dis. 1969 Mar;11(5):431-42 - PubMed
  37. Circulation. 1992 Nov;86(5 Suppl):II371-6 - PubMed
  38. Am J Physiol. 1962 Feb;202:232-6 - PubMed
  39. Circ Res. 1986 Jan;58(1):96-108 - PubMed
  40. Life Sci. 1999 Oct 29;65(23):PL273-9 - PubMed
  41. Circulation. 1997 Feb 18;95(4):988-96 - PubMed
  42. Cell Biol Toxicol. 1992 Jan-Mar;8(1):63-73 - PubMed
  43. Circ Res. 1992 Jul;71(1):127-36 - PubMed
  44. J Mol Cell Cardiol. 1997 Feb;29(2):439-48 - PubMed
  45. Circulation. 1993 Sep;88(3):864-75 - PubMed
  46. Life Sci. 1997;61(16):PL 227-34 - PubMed
  47. Am J Cardiol. 1990 Jan 2;65(2):3A-11A; discussion 35A-36A - PubMed
  48. Age Ageing. 1980 May;9(2):112-6 - PubMed
  49. Circ Res. 1993 Jan;72(1):102-11 - PubMed
  50. Gen Physiol Biophys. 1999 Dec;18 Suppl 1:19-25 - PubMed
  51. Am Heart J. 1964 Feb;67:200-20 - PubMed
  52. Int J Cardiol. 1990 Feb;26(2):129-36 - PubMed
  53. Arch Inst Cardiol Mex. 1946 Jul;16(3):205-65 - PubMed
  54. Circ Res. 1989 Dec;65(6):1565-79 - PubMed
  55. Am J Cardiol. 1966 Apr;17(4):528-34 - PubMed
  56. Life Sci. 1979 Oct 15;25(16):1397-406 - PubMed
  57. Mol Cell Biochem. 2000 Jul;210(1-2):75-80 - PubMed
  58. Am J Cardiol. 1973 Dec;32(7):982-7 - PubMed
  59. Circulation. 1991 Jun;83(6):2067-75 - PubMed
  60. Adv Cardiol. 1978;25:119-29 - PubMed
  61. Circ Res. 1990 Nov;67(5):1115-23 - PubMed
  62. Am J Physiol. 1987 Oct;253(4 Pt 1):C607-12 - PubMed
  63. Circ Res. 1988 Apr;62(4):811-32 - PubMed
  64. J Mol Cell Cardiol. 1994 Aug;26(8):1007-15 - PubMed
  65. Trends Cardiovasc Med. 1992 Mar-Apr;2(2):56-60 - PubMed
  66. Fed Proc. 1984 Sep;43(12):2692-6 - PubMed
  67. J Physiol. 1975 Sep;250(2):231-45 - PubMed
  68. Am J Physiol. 1990 May;258(5 Pt 2):H1439-48 - PubMed
  69. Circ Res. 1991 May;68(5):1378-89 - PubMed
  70. Gen Pharmacol. 1989;20(3):269-75 - PubMed
  71. Jpn Heart J. 1986 May;27(3):365-75 - PubMed
  72. Life Sci. 1995 Nov 17;57(26):PL393-9 - PubMed
  73. Cardiovasc Res. 1997 Mar;33(3):503-17 - PubMed

Publication Types